Search published articles


Showing 3 results for Treatment Outcome
Treatment of lower limbs Telangiectasias with a 1064 nm long-pulsed Nd:YAG laser
Amirhoushang Ehsani, Hasan Hajmohammadtaghiseyrafi, Pedram Nourmohammadpour, Mahdi Naghdipour, Mina Koohian Mohammadabadi, Ala Ehsani, Amirhossein Rahimnia,
Volume 14, Issue 1 (5-2023)
Abstract

Background and Aim: Lower limb telangiectasias are commonly seen in the general population and especially in females. This disorder not only causes cosmetic problems but also can cause pain and related problems of increased venous blood pressure. These varicose veins are one of the most common causes that patients refer to dermatology clinics. Considering some complications and limitations of sclerotherapy, we decided to investigate the efficacy and safety of the Long-Pulsed Nd:YAG 1064-nm laser as an alternative method.
 

Methods: 29 patients underwent at least three sessions of 1064 nm Nd: YAG laser treatment at intervals of 4 weeks. Before the first treatment session, after each session, and six months after the last session, photos were taken of the treatment site. Finally, clinical response and satisfaction rate with the treatment were recorded based on the score of a secondary dermatologist and the patient himself based on the improvement criteria from 0 to 4.
 

Results: According to the dermatologist's judgment, the average satisfaction with the treatment is 3.38 out of 4 with a standard deviation of 0.5, and based on the patient's assessment, it is 3.2 out of 4 with a standard deviation of 0.71, which is equivalent to more than 76% of the effectiveness of Nd:YAG 1064 nm laser in the treatment of telangiectatic veins. The pain during laser treatment was recorded as 6.27 with a standard deviation of 2.64 based on The VAS Scale.
 

Conclusion: Our experience has demonstrated that the long-pulsed 1064 nm Nd:YAG laser is an effective, reliable, safe method in the treatment of telangiectatic and reticular veins of the lower limbs with minimal side effects and complications.


Botulinum toxins, Masport® vs Dyston®: Comparison of efficacy, side effects and duration of effect
Ala Ehsani, Amirhoushang Ehsani, Zahra Razavi, Mina Koohian Mohammadabadi, Mahshidsadat Ansari, Zeynab Aryanian, Pedram Nourmohammadpour, Amirmohammad Almasi, Amirhossein Rahimnia,
Volume 15, Issue 2 (8-2024)
Abstract

Background and aim: As the use of botulinum toxin to treat glabellar lines increases, particularly in Iran, where foreign products (e.g. Dysport) are relatively expensive, it becomes important to compare the efficacy, side effects, and duration of action of two locally produced botulinum toxin brands, Masport® and Dyston®. This study seeks to assess and compare the treatment results of these two medications.
 

Methods: In this cross-sectional, descriptive, retrospective study, the medical records of 81 patients who visited Razi Dermatology Hospital for the treatment of moderate to severe glabellar lines were reviewed. Data related to patient satisfaction, duration of action, and side effects of Masport® and Dyston® botulinum toxin were collected and analyzed via a questionnaire.
 

Results: The mean satisfaction score was 7 for the Dyston® group and 7.7 for the Masport® group, with no statistically significant difference between the two groups (P=0.142). Additionally, the mean duration of action was 3.5 months for Dyston® and 3.8 months for Masport®, with no significant difference observed. Headache was the most common side effect reported, with no other major adverse events noted. Furthermore, there was no statistically significant difference in the incidence of side effects between the two groups.
 

Conclusion: The findings of this study indicate that both Dyston® and Masport® have similar efficacy and safety profiles. The choice between them can be primarily based on cost and patient or physician preference rather than any significant therapeutic differences. Larger studies are recommended to further validate these findings.


A comprehensive overview of pityriasis lichenoides: clinical features and treatment responses
Ala Ehsani, Seyedamirmohamad Rezaei Majd, Amirhoushang Ehsani, Pedram Nourmohammadpour, Mina Koohian Mohammadabadi, Zahra Razavi, Mahshid-Ol-Sadat Ansari, Reyhaneh Seyf, Amirhossein Rahimnia,
Volume 15, Issue 3 (11-2024)
Abstract
Background and aim: Pityriasis lichenoides (PL) is a rare papulosquamous disorder with an unknown etiology. Due to limited recent studies on this subject, the present research was conducted to describe the clinical manifestations and treatment course of these patients.
Methods: This retrospective cross-sectional study (2019-2023) was conducted on patients diagnosed with PL at Razi Dermatology Hospital, Tehran University of Medical Sciences, Iran confirmed by biopsy of skin lesions. Basic information was obtained from hospital records, and treatment follow-up was gathered from medical files and phone interviews with patients. Data were analyzed using R software, with a P<0.05 considered statistically significant.
Results: A total of 147 patients were evaluated. No significant difference was found between genders (P=0.358). The predominant subtype was PLC (91.8%), with a mean age of onset of 29.79 ± 18.73 years. The most common type of skin lesion was papules (48.4%), and generalized body involvement was the most frequent manifestation, observed in 58 patients (32.4%). The most commonly used treatment was topical corticosteroids, administered to 86 patients (52.4%). The average duration from onset to full recovery was 160.80±221.40 days. A total of 45 patients (30.6%) reported recurrent episodes of the disease. No significant association was found between treatment efficacy and gender (P=0.620), underlying conditions (P=0.293), or age (P=0.876).
Conclusion: Given the limited clinical data on patients with pityriasis lichenoides, establishing an electronic database and a national registry system for this condition is recommended.
Page 1 from 1     

© 2026 , Tehran University of Medical Sciences, CC BY-NC 4.0

Designed & Developed by : Yektaweb